Molecular insights into ligand recognition and G protein coupling of the neuromodulatory orphan receptor GPR139

Yali Zhou, Henrik Daver, Boris Trapkov, Lijie Wu, Meng Wu, Kasper Harpsøe, Patrick R. Gentry, Kaiwen Liu, Marina D. Larionova, Junlin Liu, Na Chen, Hans Bräuner‐Osborne, David E. Gloriam, Tian Hua, Zhi‐Jie Liu, Zhijie LiuCell 2021 · DOI · OpenAlex

Abstract

The G protein-coupled receptor GPR139 is a key target for neuromodulation, with agonists currently in clinical trials for treating cognitive impairment and schizophrenia. Although classified as an orphan receptor, GPR139 is activated by amino acids like L-Trp and L-Phe, primarily triggering the Gq/11 pathway. It acts as a regulator of μ-opioid and dopamine signaling in the central nervous system. Until now, the structural basis for its ligand recognition and G protein coupling remained unknown. This paper presents cryo-electron microscopy (cryo-EM) structures of GPR139 in complex with the agonist JNJ-63533054 and various G proteins (miniGs/q and Gi), including rare intermediate states bound to GDP and GTP.

Introduction

GPR139 is a Class A GPCR highly expressed in the brain, where it modulates critical neurotransmitter systems. Its therapeutic potential for treating the negative symptoms of schizophrenia has made it a high-priority target. However, the lack of structural data has hindered our understanding of how it recognizes ligands and selects between different intracellular signaling pathways. Most GPCR structures are captured in a nucleotide-free state; this study addresses that gap by capturing the receptor in physiologically relevant intermediate states bound to GDP and GTP.

Methods

The research team utilized high-resolution cryo-EM (3.2 Å to 3.8 Å) to solve the structures of GPR139. They employed several stabilization techniques, including the use of a Xylanase fusion protein and specific mutations like S62(2x39)V. To observe the G protein activation cycle, they used chimeric miniGs/q and heterotrimeric Gi proteins, adding GDP or GTP before sample freezing. These structural models were further validated using Bioluminescence Resonance Energy Transfer (BRET) functional assays and Molecular Dynamics simulations.

Key Structural Insights

The R244 Anchor and Binding Pocket

A defining feature of the GPR139 binding pocket is the presence of Arginine 244 (R244 at position 6x51), a residue that is typically hydrophobic in other Class A GPCRs. R244 acts as a critical anchor, forming hydrogen bonds with the agonist. Mutating this residue almost entirely abolishes receptor activity, highlighting its functional importance. The study also identified a "negatively charged wall" of residues that likely funnels ligands into the binding pocket via electrostatic interactions.

Structural details of the GPR139 binding pocket (g, h) and functional BRET assays (i, j) validating the role of key residues like R244 and W166 in G protein coupling.

Ligand Pose Shifting and Activation Intermediates

One of the most significant findings is that the agonist JNJ-63533054 adopts different orientations, or "poses," depending on the G protein it is coupled with and the presence of nucleotides. This suggests a bidirectional allosteric communication where the state of the G protein influences the shape of the drug-binding pocket. By capturing GDP- and GTP-bound states, the authors visualized the mechanical movement of the G protein's α5 helix as it inserts into the receptor core during activation.

Cryo-EM density maps and atomic models of GPR139 in complex with miniGs/q (GTP/GDP bound) and Gi, illustrating ligand pose shifting and G protein activation intermediates.

Discussion and Future Directions

This study provides a comprehensive structural blueprint for GPR139, explaining its unique ligand recognition mechanism and pathway selectivity. While the use of a surrogate agonist (JNJ-63533054) provided high-resolution data, future work is needed to experimentally resolve the binding of endogenous ligands like L-Tryptophan. The discovery of intermediate nucleotide-bound states provides a new template for understanding the universal mechanics of GPCR-G protein signaling, which could lead to more precise drug design for CNS disorders.

Summary updated

Abstract

The G protein-coupled receptor GPR139 is involved in neuromodulation, and one of its agonists is in clinical trials for the treatment of cognitive impairment and negative symptoms of schizophrenia. While GPR139 is a understudied ‘orphan’ receptor, it can be activated by the amino acids L-Trp, L-Phe1 or α-Melanocyte-stimulating hormone (α-MSH) which is an endogenous agonist of melanocortin receptors.2,3 GPR139 activation triggers several G protein pathways of which Gq/11 is the primary.4,5,6,7 Of note, the expression of GPR139 correlates with that of the μ-opioid and dopamine D2 receptors in a broad range of the central nervous system (CNS), which acts as a regulator of μ-opioid and dopamine signaling.6,7,8,9 For example, GPR139 antagonist JNJ-3792165 increases the sensitivity of the μ-opioid receptor to morphine.6 Hitherto, the structural basis of how ligands interact with and activate GPR139 to transduce diverse signals has remained unknown. Furthermore, the more physiologically relevant intermediate states of GPCR–G protein complex structures in the nucleotide-bound forms are also elusive. Here, we report the cryo-electron microscopy (cryo-EM) structures of GPR139 in complex with a key reference ligand JNJ-63533054 which is an analog of agent TAK-04110 in clinical trial, and miniGs/q or Gi in nucleotide-free form, as well as the GPR139–JNJ-63533054–miniGs/q complex in GDP- and GTP-bound states, respectively (Fig. 1a–f).
BibTeX
@inproceedings{zhou2021molecular,
  author = {Yali Zhou and Henrik Daver and Boris Trapkov and Lijie Wu and Meng Wu and Kasper Harpsøe and Patrick R. Gentry and Kaiwen Liu and Marina D. Larionova and Junlin Liu and Na Chen and Hans Bräuner‐Osborne and David E. Gloriam and Tian Hua and Zhi‐Jie Liu and Zhijie Liu},
  title = {{Molecular insights into ligand recognition and G protein coupling of the neuromodulatory orphan receptor GPR139}},
  booktitle = {Cell},
  year = {2021},
  doi = {10.1038/s41422-021-00591-w},
}
Figure